LAVA Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jan 1, 2020
Revenue	12.54	6.77	19.39	5.35	3.75	-
Revenue Growth (YoY)	-36.01%	-65.09%	262.45%	42.78%	-	-
Cost of Revenue	2.55	3.48	-	-	15.7	8.35
Gross Profit	9.99	3.29	19.39	5.35	-11.95	-8.35
Selling, General & Admin	11.77	12.73	14.12	12.02	2.72	1.24
Research & Development	29.88	33.81	40.11	36.95	-	-
Operating Expenses	41.65	46.54	54.23	48.96	2.72	1.24
Operating Income	-31.67	-43.25	-34.84	-43.61	-14.67	-9.58
Interest Expense	-	-	-	-0.63	-0.34	-0.09
Interest & Investment Income	3.16	2.97	0.26	-	-	-
Currency Exchange Gain (Loss)	0.19	-1.41	2.92	2.04	-0.87	-0.02
Pretax Income	-28.31	-41.7	-31.66	-42.2	-15.88	-9.69
Income Tax Expense	0.28	0.28	0.25	0.16	0.04	-
Net Income	-28.59	-41.97	-31.91	-42.36	-15.93	-9.69
Net Income to Common	-28.59	-41.97	-31.91	-42.36	-15.93	-9.69
Shares Outstanding (Basic)	27	27	26	20	0	0
Shares Outstanding (Diluted)	27	27	26	20	0	0
Shares Change (YoY)	3.10%	3.12%	31.21%	4850.36%	-10.81%	-
EPS (Basic)	-1.06	-1.57	-1.23	-2.14	-39.90	-21.65
EPS (Diluted)	-1.06	-1.57	-1.23	-2.14	-39.90	-21.65
Free Cash Flow	-31.99	-39.7	3.46	-29.41	-9.81	-9.38
Free Cash Flow Per Share	-1.19	-1.49	0.13	-1.49	-24.58	-20.95
Gross Margin	79.64%	48.56%	100.00%	100.00%	-	-
Operating Margin	-252.58%	-638.99%	-179.66%	-815.20%	-391.59%	-
Profit Margin	-228.02%	-	-164.55%	-	-	-
Free Cash Flow Margin	-255.18%	-586.53%	17.82%	-549.74%	-261.78%	-
EBITDA	-31.04	-42.64	-34.33	-43.28	-14.46	-9.48
EBITDA Margin	-247.55%	-	-177.06%	-	-	-
D&A For EBITDA	0.63	0.62	0.5	0.33	0.21	0.1
EBIT	-31.67	-43.25	-34.84	-43.61	-14.67	-9.58
EBIT Margin	-252.58%	-	-179.66%	-	-	-
Revenue as Reported	-	-	-	-	3.75	-

Source: S&P Capital IQ. Standard template.